The role and mechanisms of action of microRNAs in cancer drug resistance

W Si, J Shen, H Zheng, W Fan - Clinical epigenetics, 2019 - Springer
MicroRNAs (miRNAs) are small non-coding RNAs with a length of about 19–25 nt, which
can regulate various target genes and are thus involved in the regulation of a variety of …

Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade

Z Chen, T Shi, L Zhang, P Zhu, M Deng, C Huang, T Hu… - Cancer letters, 2016 - Elsevier
Multidrug resistance (MDR) is a serious phenomenon employed by cancer cells which
hampers the success of cancer pharmacotherapy. One of the common mechanisms of MDR …

[HTML][HTML] The different mechanisms of cancer drug resistance: a brief review

B Mansoori, A Mohammadi, S Davudian… - Advanced …, 2017 - ncbi.nlm.nih.gov
Anticancer drugs resistance is a complex process that arises from altering in the drug
targets. Advances in the DNA microarray, proteomics technology and the development of …

MicroRNA: A novel target of curcumin in cancer therapy

H Mirzaei, A Masoudifar, A Sahebkar… - Journal of cellular …, 2018 - Wiley Online Library
Curcumin is known as a natural dietary polyphenol which is extracted from Curcuma longa
L. It has been shown that curcumin has a variety of pharmacological effects such as …

Molecular mechanisms of drug resistance in ovarian cancer

L Norouzi‐Barough, MR Sarookhani… - Journal of cellular …, 2018 - Wiley Online Library
Ovarian cancer is the most lethal malignancy among the gynecological cancers, with a 5‐
year survival rate, mainly due to being diagnosed at advanced stages, recurrence and …

MicroRNA biogenesis, gene silencing mechanisms and role in breast, ovarian and prostate cancer

S Khan, H Ayub, T Khan, F Wahid - Biochimie, 2019 - Elsevier
Micro-ribonucleic acids (miRNAs) are important class of short regulatory RNA molecules
involved in regulation of several essential biological processes. In addition to Dicer and …

Understanding the role of the transcription factor Sp1 in ovarian cancer: from theory to practice

B Vellingiri, M Iyer, M Devi Subramaniam… - International journal of …, 2020 - mdpi.com
Ovarian cancer (OC) is one of the deadliest cancers among women contributing to high risk
of mortality, mainly owing to delayed detection. There is no specific biomarker for its …

miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin

X Zhu, H Shen, X Yin, L Long, C Xie, Y Liu, L Hui, X Lin… - Oncogene, 2016 - nature.com
Epithelial–mesenchymal transition (EMT) has an established role in promoting tumor
progression and the acquisition of therapeutic resistance. Here, the EMT phenotype was …

The network of non-coding RNAs in cancer drug resistance

F Corrà, C Agnoletto, L Minotti, F Baldassari… - Frontiers in …, 2018 - frontiersin.org
Non-coding RNAs (ncRNAs) have been implicated in most cellular functions. The disruption
of their function through somatic mutations, genomic imprinting, transcriptional and post …

miR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes

X Li, W Chen, Y Jin, R Xue, J Su, Z Mu, J Li… - Biochemical …, 2019 - Elsevier
Chemotherapy is the preferred treatment for advanced ovarian cancer, but the 5-year
survival rate remains low partly because of the development of drug resistance. Although it …